ID: ALA238913

Max Phase: Preclinical

Molecular Formula: C30H30N3O5P

Molecular Weight: 543.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  N=C(N)c1ccc(CCC(NC(=O)OCc2ccccc2)P(=O)(Oc2ccccc2)Oc2ccccc2)cc1

Standard InChI:  InChI=1S/C30H30N3O5P/c31-29(32)25-19-16-23(17-20-25)18-21-28(33-30(34)36-22-24-10-4-1-5-11-24)39(35,37-26-12-6-2-7-13-26)38-27-14-8-3-9-15-27/h1-17,19-20,28H,18,21-22H2,(H3,31,32)(H,33,34)

Standard InChI Key:  MWBNFSUYTZMPST-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 543.56

Molecular Weight (Monoisotopic): 543.1923

AlogP: 6.51

#Rotatable Bonds: 12

Polar Surface Area: 123.73

Molecular Species: BASE

HBA: 6

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.11

CX Basic pKa: 11.49

CX LogP: 6.04

CX LogD: 3.71

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.11

Np Likeness Score: -0.14

References

1. Joossens J, Ali OM, El-Sayed I, Surpateanu G, Van der Veken P, Lambeir AM, Setyono-Han B, Foekens JA, Schneider A, Schmalix W, Haemers A, Augustyns K..  (2007)  Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.,  50  (26): [PMID:18052026] [10.1021/jm700962j]

2. van Soom J, Cuzzucoli Crucitti G, Gladysz R, van der Veken P, Di Santo R, Stuyver I, Buck V, Lambeir A, Magdolen V, Joossens J, Augustyns K.  (2015)  The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics,  6  (11): [10.1039/C5MD00288E]

Source

Source(1):

• Scientific Literature